PAWS subsidiary Mesa Pharmacy executes marketing agreement

SHOWS STRONG SALES IN JANUARY AND CONTINUED GROWTH IN FEBRUARY.

IRVINE, CA, Feb. 19, 2014  - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that Mesa Pharmacy Inc. ("Mesa") has executed a marketing agreement with Trestles Pain Specialists LLC of San Juan Capistrano, California to expand sales within California and, eventually, in other states.  Physician groups and industrial medical clinics in the central valley of California and other new locations throughout California will now be using the alternative transdermal medications Mesa compounds.

Mesa Pharmacy's Sales exceed $3,600,000 in November. Audit Nearly Complete. Acquisition May Be Completed Soon

FDA Reclassification of Hydrocodone to Schedule II Could Boost Sales.

PALO ALTO, CA, Dec. 5, 2013 - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that work on the name change to Praxsyn Corporation is nearing completion and that the Company expects to be able to file a request with FINRA early next week along with filing the necessary filings and disclosures with the SEC and the State of Illinois.

The PAWS Pet Company, Inc. Executes Agreement to Acquire MESA Pharmacy, Inc. Orders expected to exceed $25 Million in 2014

PALO ALTO, CA, Oct. 29, 2013 -- The PAWS Pet Company, Inc. (otcqb:PAWS), announced it has executed an agreement to acquire MESA Pharmacy, Inc. as part of its new strategy to become a dominant player in the delivery of compounded pharmaceutical products to consumers.
 

Pages